Bronchial Asthma Clinical Trial
Official title:
Health-Related Quality of Life of Patients With Asthma and Its Associated Factors During the Pandemic of COVID-19
Nowadays, the COVID-19 epidemic causes stress not only to healthy people but also to people with unhealthy conditions. Excess psychological stress (either in quality, quantity, frequency, and/or duration) could push susceptible individuals to ultimately develop clinical asthma. Depression was significantly associated with asthma interference with daily activities, breathlessness, night symptoms, use of bronchodilators, and poor compliance with medical treatment. Covid-19 pandemic induced the countries around the world to require from its citizens not to ask for health care support rather than in emergency situations and through utilizing telemedicine. This action aims to control spreading the infection with viruses as well as to reduce the workload on the healthcare providers. Although asthma is not listed as one of the chronic conditions that might complicate coronavirus infections, asthma people might have a high-stress level that might induce their asthma attack which consequentially reflects on their quality of life. People with asthma have a unique experience rather than people with other health conditions during COVID-19. Patients with asthma experience a lot of stressors that might induce asthma and impaired their HRQOL such as overuse of antiseptic substances, stay home with a sedentary lifestyle, the sudden shift to telemedicine, and electronic work from home. Also, as a result of the similarity of asthma symptoms with coronavirus symptoms, the patient might have a continuous sense of uncertainty that s/he is infected with the COVID-19 virus, and this suspicion can increase the psychological overburden on these patients. Therefore, all these stressors should be evaluated to recognize their health needs and the kind of social and health support that should be provided to them during the pandemic time. Also, Identifying the predictors of HRQOL among patients with asthma during the pandemic of COVID-19 is urgently required.
Asthma is a chronic inflammatory disease of the lower respiratory tract which derives from a combination of genetic predisposition with environmental exposure to several factors. It is a chronic respiratory disease that results in morbidity, mortality, and impaired health-related quality of life (HRQoL). It is estimated that 334 million people have asthma worldwide. Nowadays, the COVID-19 epidemic causes stress not only to healthy people but also to people with unhealthy conditions. Excess psychological stress (either in quality, quantity, frequency, and/or duration) could push susceptible individuals to ultimately develop clinical asthma. Depression was significantly associated with asthma interference with daily activities, breathlessness, night symptoms, use of bronchodilators, and poor compliance with medical treatment. Covid-19 pandemic induced the countries around the world to require from its citizens not to ask for health care support rather than in emergency situations and through utilizing telemedicine. This action aims to control spreading the infection with viruses as well as to reduce the workload on the healthcare providers. Although asthma is not listed as one of the chronic conditions that might complicate coronavirus infections, asthma people might have a high-stress level that might induce their asthma attack which consequentially reflects on their quality of life. People with asthma have a unique experience rather than people with other health conditions during COVID-19. Patients with asthma experience a lot of stressors that might induce asthma and impaired their HRQOL such as overuse of antiseptic substances, stay home with a sedentary lifestyle, the sudden shift to telemedicine, and electronic work from home. Also, as a result of the similarity of asthma symptoms with coronavirus symptoms, the patient might have a continuous sense of uncertainty that s/he is infected with the COVID-19 virus, and this suspicion can increase the psychological overburden on these patients. Therefore, all these stressors should be evaluated to recognize their health needs and the kind of social and health support that should be provided to them during the pandemic time. Also, Identifying the predictors of HRQOL among patients with asthma during the pandemic of COVID-19 is urgently required. A cross-sectional analytical design will be utilized. The study participants will be adults (18 years or older) who have been diagnosed with bronchial asthma or pulmonary disease. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02934945 -
Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients
|
Phase 4 | |
Completed |
NCT02561351 -
Correlation Between Fractional Exhaled Nitric Oxide (FeNO) Levels and Asthma Exacerbation
|
N/A | |
Recruiting |
NCT01759472 -
Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Provocation Test
|
N/A | |
Completed |
NCT01918293 -
Self-Management Using Smartphone Application for Chronic Disease Care in Real siTuation (SMART-Asthma): Adult
|
N/A | |
Completed |
NCT01203904 -
Pulmicort Turbuhaler 100/200 Specific Clinical Experience Investigation
|
N/A | |
Completed |
NCT00536731 -
Symbicort Rapihaler Therapeutic Equivalence Study
|
Phase 3 | |
Completed |
NCT01762917 -
Influence of Bag Volume Variation on the Reproducibility of Inert Gas Rebreathing
|
N/A | |
Completed |
NCT00331929 -
Respiratory Health Study of Children in Kiryat Tivon
|
N/A | |
Completed |
NCT00930826 -
Childhood Asthma and Schooling: The Truth Unveiled
|
N/A | |
Completed |
NCT00327028 -
Study of Efficacy of Phenytoin in Therapy of Patients With Bronchial Asthma
|
Phase 4 | |
Completed |
NCT00413387 -
Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)
|
Phase 3 | |
Completed |
NCT00153283 -
Study of Efficacy of Gabapentin in Therapy of Bronchial Asthma
|
Phase 4 | |
Completed |
NCT00950794 -
Study of Salmeterol (SN408D) for Adult Asthma
|
Phase 4 | |
Completed |
NCT00142025 -
Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma
|
Phase 4 | |
Completed |
NCT00153270 -
Study of Efficacy of Sodium Valproate in Therapy of Bronchial Asthma
|
Phase 4 | |
Completed |
NCT03450434 -
XC8 in the Treatment of Patients With Bronchial Asthma
|
Phase 2 | |
Recruiting |
NCT05189613 -
Mepolizumab Effectiveness in Severe Eosinophilic Asthma and Bronchiectasis
|
N/A | |
Recruiting |
NCT04128111 -
Study on the Correlation Between TCM Syndrome, Inflammatory Phenotype and Biomarker of Bronchial Asthma
|
||
Completed |
NCT06326632 -
Comparative Effectiveness Study of Constant-Load Versus Graded Aerobic Exercise in Obese Children With Bronchial Asthma
|
N/A | |
Completed |
NCT05088512 -
The Role of Genetic Factors in the Development of Bronchial Asthma in the Kazakh Population
|